Location History:
- Göeborg, SE (2001)
- Göteborg, SE (2001 - 2003)
- Goteborg, SE (1998 - 2004)
- Gothenburg, SE (2002 - 2005)
Company Filing History:
Years Active: 1998-2005
Title: Innovations by Inventor Kristoffer Hellstrand
Introduction
Kristoffer Hellstrand is a prominent inventor based in Gothenburg, Sweden. With a remarkable portfolio of 16 patents, he has made significant contributions to the field of pharmaceutical compositions and methods, particularly focusing on the maturation of monocytes.
Latest Patents
Among his latest innovations, Hellstrand has developed methods and compositions for promoting the maturation of monocytes. This groundbreaking work discloses a method that involves administering a reactive oxygen species (ROS) inhibitor or scavenger alongside at least one monocyte maturation-promoting agent. The pharmaceutical composition created includes a compound effective in enhancing the maturation of monocytes, combined with a ROS inhibitor or scavenger in a pharmaceutically acceptable carrier. Such advancements are crucial for therapeutic applications in immunology.
Career Highlights
Kristoffer Hellstrand is affiliated with Maxim Pharmaceuticals, Inc., where he has greatly influenced research and development initiatives. His diverse expertise has not only propelled advancements in monocyte maturation but has also positioned him as a leading figure in pharmaceutical innovation.
Collaborations
Throughout his career, Hellstrand has collaborated with notable colleagues, including Svante Hermod Hermodsson and Kurt R Gehlsen. Together, they have contributed to the progression of medical science, sharing knowledge and expertise that continue to fuel research and innovation in their field.
Conclusion
In summary, Kristoffer Hellstrand stands out as a significant inventor in the pharmaceutical industry. His inventions and collaborations exemplify the spirit of innovation and research excellence that drives advancements in medical science, particularly in the area of immunology. With a focus on enhancing monocyte maturation, Hellstrand's work holds promise for future therapeutic developments.